Toll-like receptor 2 and 4 expression after severe injury is not involved in the dysregulation of the innate immune system

Journal of Trauma - Injury, Infection and Critical Care

Volumn 63, Issue 4, 2007, Pages 740-746

  Lendemans, Sven ^a   Kreuzfelder, Ernst ^a   Rani, Meenakshi ^a   Bayeeh, Emilie ^a   Schade, F Ulrich ^a   Flohé, Stefanie B ^a   Waydhas, Christian ^a   Flohé, Sascha ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CD14; Endotoxin; Sepsis; Toll like receptor 2; Toll like receptor 4; Trauma

Indexed keywords

CYTOKINE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BACTERIAL CELL WALL; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEPARINIZATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INJURY SCALE; INNATE IMMUNITY; MALE; MONOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD14; CYTOKINES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PEPTIDOGLYCAN; PROSPECTIVE STUDIES; REFERENCE VALUES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 37349017570     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/01.ta.0000240451.42238.d1     Document Type: Article

References (32)

1. Fabian TC, Croce MA, Fabian MJ, et al. Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery. 1995;118:63-72.
2. Majetschak M, Flach R, Heukamp T, et al. Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. J Trauma. 1997;43:880-887.
3. Adib-Conquy M, Moine P, Asehnoune K, et al. Toll-like receptor-mediated tumor necrosis factor and interleukin-10 production differ during systemic inflammation. Am J Respir Crit Care Med. 2003;168:158-164.
4. O'Sullivan ST, Lederer JA, Horgan AF, et al. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg. 1995;222:482-492.
5. Schwacha MG, Schneider CP, Bland KI, et al. Resistance of macrophages to the suppressive effect of interleukin-10 following thermal injury. Am J Physiol Cell Physiol. 2001;281:C1180-C1187.
6. Faist E, Mewes A, Strasser T, et al. Alteration of monocyte function following major injury. Arch Surg. 1988;123:287-292.
7. Majetschak M, Krehmeier U, Bardenheuer M, et al. Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood. 2002;101:1882-1890.
8. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499-511.
9. Bazil V, Baudys M, Hilgert I, et al. Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14. Mol Immunol. 1989;26:657-662.
10. Schwandner R, Dziarski R, Wesche H, et al. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274:17406-17409.
11. Nakao Y, Funami K, Kikkawa S, et al. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. J Immunol. 2005;174:1566-1573.
12. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-1655.
13. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707-710.
14. Ikushima H, Nishida T, Takeda K, et al. Expression of Toll-like receptors 2 and 4 is downregulated after operation. Surgery. 2004;135:376-385.
15. Laudanski K, De A, Brouxhon S, et al. Abnormal PGE(2) regulation of monocyte TNF-alpha levels in trauma patients parallels development of a more macrophage-like phenotype. Shock. 2004;22:204-212.
16. Adib-Conquy M, Cavaillon JM. Gamma interferon and granulocyte/monocyte colony-stimulating factor prevent endotoxin tolerance in human monocytes by promoting interleukin-1 receptor-associated kinase expression and its association to MyD88 and not by modulating TLR4 expression. J Biol Chem. 2002;277:27927-27934.
17. Majetschak M, Flach R, Kreuzfelder E, et al. The extent of traumatic damage determines a graded depression of the endotoxin responsiveness of peripheral blood mononuclear cells from patients with blunt injuries. Crit Care Med. 1999;27:313-318.
18. Venet F, Pachot A, Debard AL, et al. Increased percentage of CD4+CD25+ regulatory T cells during septic shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med. 2004;32:2329-2331.
19. Murphy TJ, Choileain NN, Zang Y, Mannick JA, Lederer JA. CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol. 2005;174:2957-2963.
20. Boergermann J, Friedrich I, Flohé S, et al. Tumor necrosis factor-alpha production in whole blood after cardiopulmonary bypass: downregulation caused by circulating cytokine-inhibitory activities. J Thorac Cardiovasc Surg. 2002;124:608-617.
21. Neuhof C, Wendling J, Dapper F, et al. Endotoxemia and cytokine generation in cardiac surgery in relation to flow mode and duration of cardiopulmonary bypass. Shock. 2001;1:39-43.
22. Dybdahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation. 2002;12:105:685-690.
23. Haerter L, Mica L, Stocker R, et al. Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock. 2004;22:403-409.
24. Calvano JE, Agnese DM, Um JY, et al. Modulation of the lipopolysaccharide receptor complex (CD14, TLR4, MD-2) and toll-like receptor 2 in systemic inflammatory response syndrome-positive patients with and without infection: relationship to tolerance. Shock. 2003;20:415-419.
25. Armstrong L, Medford AR, Hunter KJ, et al. Differential expression of toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol. 2004;136:312-319.
26. Paterson HM, Murphy TJ, Purcell EJ, et al. Injury primes the innate immune system for enhanced toll-like receptor reactivity. J Immunol. 2003;171:1473-1483.
27. Rosati O, Martin MU. Identification and characterization of murine IRAK-M. Biochem Biophys Res Commun. 2003;293:1472-1477.
28. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of toll-like receptor signaling. Cell. 2002;110:191-202.
29. Medvedev AE, Lentschat A, Wahl LM, et al. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol. 2002;169:5209-5216.
30. Escoll P, del Fresno C, Garcia L, et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun. 2003;311:465-472.
31. Maung AA, Fujimi S, Miller ML, MacConmara MP, Mannick JA, Lederer JA. Enhanced TLR4 reactivity following injury is mediated by increased p38 activation. J Leukoc Biol. 2005;78:565-573.
32. Toetemeyer S, Kaiser P, Maskell DJ, Bryant CE. Sublethal infection of C57BL/6 miche with Salmonella enterica serovar typhimurium leads to an increase in levels of Toll-like receptor 1 (TLR1), TLR2 and TLR9 mRNA as well as a decrease in levels of TLR6 mRNA in infected organs. Infect Immun. 2005;73:1873-1878.